Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)

Update l'année dernière
Reference: NCT03145220

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -


EA-230 is a newly developed synthetic compound with anti-inflammatory properties, it is a linear tetrapeptide derived from the human chorionic gonadotropin hormone (hCG). Recently, its immunomodulatory effects in humans were confirmed in a phase I trial and an optimal dose was established. To establish this anti-inflammatory effect in a selected patient population and assess clinical outcome, a combined phase IIa/IIb trial will be conducted with patients undergoing cardiac surgery.

Inclusion criteria

  • Systemic inflammatory response syndrome,Coronary Artery Bypass Grafting